ArticleFrontiers in veterinary science2026
Microencapsulation of cholic acid via complex coacervation enhances sustained release and antibacterial activity against
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop a microencapsulated cholic acid (CA) preparation to improve the stability, sustained-release performance, and antibacterial activity of CA for potential use in antibiotic-free animal production. CA microcapsules were prepared by complex coacervation using gelatin and gum arabic as wall materials, and the formulation was optimized by single-factor and orthogonal experimental designs. The optimal preparation conditions were a wall material concentration of 2.5%, a core-to-wall ratio of 1.8:1, and pH 4.1, yielding a drug loading rate of 49.73% and an encapsulation efficiency of 88.76%. The microcapsules showed spherical morphology, low hygroscopicity, improved thermal and storage stability, and a sustained-release profile over 72 h in simulated gastrointestinal media. Both free CA and microencapsulated CA significantly inhibited
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.